초록 ▼

In one aspect the invention provides compilations of nucleic acids, articles of manufacture, e.g., arrays, and methods for the detection of chromosomal abnormalities, such as a chromosomal aneuploidies, deletions, amplifications, and the like, and the diagnosis or prognosis of syndromes associated w

In one aspect the invention provides compilations of nucleic acids, articles of manufacture, e.g., arrays, and methods for the detection of chromosomal abnormalities, such as a chromosomal aneuploidies, deletions, amplifications, and the like, and the diagnosis or prognosis of syndromes associated with a contiguous gene abnormality. Kits are also provided.

대표청구항 ▼

What is claimed is: 1. An array comprising: a plurality of nucleic acid segments, wherein each nucleic acid segment is immobilized to a discrete and known spot on a substrate surface to form an array of nucleic acids, and each spot comprises a segment of genomic nucleic acid selected to detect a ge

What is claimed is: 1. An array comprising: a plurality of nucleic acid segments, wherein each nucleic acid segment is immobilized to a discrete and known spot on a substrate surface to form an array of nucleic acids, and each spot comprises a segment of genomic nucleic acid selected to detect a genetic syndrome, wherein the array-immobilized genomic nucleic acid segments are covalently bound to the substrate surface through a compound having the general formula: R1--X--R2, and wherein R1 is a cyclic ether, an aldehyde, or a chloromethylphenyl moiety; X is a moiety chemically suitable for linking the R1 moiety to the R2 moiety, and the R2 moiety has the general formula wherein R3, R4 and R5 comprise identical or different alkoxy groups or chloro groups. 2. The away of claim 1, further comprising at least one spot comprising a nucleic acid segment acting as a positive control. 3. The array of claim 1, further comprising at least one spot comprising a nucleic acid segment acting as a negative control. 4. The array of claim 1, wherein the array-immobilized genomic nucleic acid segments in a first spot are non-overlapping in sequence compared to the array-immobilized genomic nucleic acid segments in a second spot. 5. The array of claim 4, wherein the array-immobilized genomic nucleic acid segments in the first spot are non-overlapping in sequence compared to the array-immobilized genomic nucleic acid segments in all other genomic nucleic acid-comprising spots on the array. 6. The array of claim 1, wherein at least one genomic nucleic acid segment is spotted in duplicate or triplicate on the array. 7. The array of claim 1, wherein the duplicate spot or triplicate spot has a different amount of nucleic acid segments immobilized. 8. The array of claim 6, wherein all the genomic nucleic acid segments are spotted in duplicate or triplicate on the array. 9. The array of claim 1, wherein about 95% of the array-immobilized genomic nucleic acid segments comprise a label. 10. The array of claim 1, wherein about 98% of the array-immobilized genomic nucleic acid segments comprise a label. 11. The array of claim 1, wherein 100% of the array-immobilized genomic nucleic acid segments comprise a label. 12. The array of claim 1, wherein at least one nucleic acid segment is cloned in a construct comprising an artificial chromosome. 13. The array of claim 12, wherein the artificial chromosome comprises a bacterial artificial chromosome (BAC). 14. The array of claim 12, wherein the artificial chromosome is selected from the group consisting of a human artificial chromosome (HAC) a yeast artificial chromosome (YAC), a transformation-competent artificial chromosome (TAC) and a bacteriophage P1-derived artificial chromosome (PAC). 15. The array of claim 1, wherein at least one nucleic acid segment is cloned in a construct comprising a vector selected from the group consisting of a cosmid vector, a plasmid vector and a viral vector. 16. The array of claim 1, wherein at least one of the nucleic acid segments is between about 50 kilobases to about 500 kilobases in length. 17. The array of claim 16, wherein the at least one nucleic acid segment is between about 100 kilobases to about 400 kilobases in length. 18. The array of claim 17, wherein the at least one nucleic acid segment is about 300 kilobases in length. 19. A compilation of nucleic acids for diagnosis of a genetic syndrome, the compilation comprising a plurality of nucleic acid segments, wherein each nucleic acid segment comprises a segment of genomic nucleic acid selected to detect a genetic syndrome, wherein the nucleic acid segments further comprise a compound having the general formula description="In-line Formulae" end="lead"R1--X--Si(OR2)m(Cl)n(R) k,description="In-line Formulae" end="tail" wherein m+k is the integer 3, and n can be 0 if m is greater than 0, or n+k is the integer 3 and m can be 0 if n is greater than 0; X is an inert linker; R1 comprises a group reactive toward the biological molecule; R is an alkyl group; and R2 is an alkyl group. 20. The compilation of nucleic acids of claim 19, wherein the nucleic acid segments further comprise a cloning vehicle. 21. The compilation of nucleic acids of claim 19, wherein the nucleic acid segments are immobilized onto a surface. 22. The compilation of nucleic acids of claim 21, wherein the nucleic acid segments are immobilized on a surface as an array. 23. The compilation of nucleic acids of claim 19, wherein about 95% of the nucleic acid segments comprise a label. 24. The compilation of nucleic acids of claim 19, wherein about 98% of the nucleic acid segments comprise a label. 25. The compilation of nucleic acids of claim 19, wherein 100% of the nucleic acid segments comprise a label. 26. The compilation of nucleic acids of claim 19, wherein at least one nucleic acid segment is cloned in a construct comprising an artificial chromosome. 27. The compilation of nucleic acids of claim 26, wherein the artificial chromosome comprises a bacterial artificial chromosome (BAC). 28. The compilation of nucleic acids of claim 26, wherein the artificial chromosome is selected from the group consisting of a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), a transformation-competent artificial chromosome (TAC) and a bacteriophage P1-derived artificial chromosome (PAC). 29. The compilation of nucleic acids of claim 19, wherein at least one nucleic acid segment is cloned in a construct comprising a vector selected from the group consisting of a cosmid vector, a plasmid vector and a viral vector. 30. The compilation of nucleic acids of claim 19, wherein the nucleic acid segments are between about 50 kilobases to about 500 kilobases in length. 31. The compilation of nucleic acids of claim 30, wherein the nucleic acid segments are between about 100 kilobases to about 400 kilobases in length. 32. The compilation of nucleic acids of claim 31, wherein the cloned nucleic acid segments are between about 150 kilobases and about 300 kilobases in length. 33. An array comprising: a plurality of nucleic acid segments, wherein each nucleic acid segment is immobilized to a discrete and known spot on a substrate surface to form an array of nucleic acids, and each spot comprises a segment of genomic nucleic acid selected to detect a genetic syndrome, wherein the array-immobilized genomic nucleic acid segments are covalently bound to the substrate surface through a compound having the general formula: R1--X--R2, wherein R1 is an amino group, R2 is an alkoxysilane group or a chlorohalide group; and X is a moiety chemically suitable for linking the R1 group and the R2 group. 34. The array of claim 31, further comprising at least one spot comprising a nucleic acid segment acting as a positive control. 35. The array of claim 31, further comprising at least one spot comprising a nucleic acid segment acting as a negative control. 36. The array of claim 31, wherein the array-immobilized genomic nucleic acid segments in a first spot are non-overlapping in sequence compared to the array-immobilized genomic nucleic acid segments in a second spot. 37. The array of claim 36, wherein the array-immobilized genomic nucleic acid segments in the first spot are non-overlapping in sequence compared to the array-immobilized genomic nucleic acid segments in all other genomic nucleic acid-comprising spots on the array. 38. The array of claim 31, wherein at least one genomic nucleic acid segment is spotted in duplicate or triplicate on the array. 39. The array of claim 38, wherein the duplicate spot or triplicate spot has a different amount of nucleic acid segments immobilized. 40. The array of claim 38, wherein all the genomic nucleic acid segments are spotted in duplicate or triplicate on the array. 41. The array of claim 31, wherein about 95% of the array-immobilized genomic nucleic acid segments comprise a label. 42. The array of claim 31, wherein about 98% of the array-immobilized genomic nucleic acid segments comprise a label. 43. The array of claim 31, wherein 100% of the array-immobilized genomic nucleic acid segments comprise a label. 44. The array of claim 31, wherein at least one nucleic acid segment is cloned in a construct comprising an artificial chromosome. 45. The array of claim 44, wherein the artificial chromosome comprises a bacterial artificial chromosome (BAC). 46. The array of claim 44, wherein the artificial chromosome is selected from the group consisting of a human artificial chromosome (HAC) a yeast artificial chromosome (YAC), a transformation-competent artificial chromosome (TAC) and a bacteriophage P1-derived artificial chromosome (PAC). 47. The array of claim 31, wherein at least one nucleic acid segment is cloned in a construct comprising a vector selected from the group consisting of a cosmid vector, a plasmid vector and a viral vector. 48. The array of claim 31, wherein at least one of the nucleic acid segments is between about 50 kilobases to about 500 kilobases in length. 49. The array of claim 48, wherein the at least one nucleic acid segment is between about 100 kilobases to about 400 kilobases in length. 50. The array of claim 49, wherein the at least one nucleic acid segment is about 300 kilobases in length. 51. A method for selecting a genomic nucleic acid segment for use as a hybridization target in a comparative genomic hybridization (CGH) reaction for the detection of a chromosomal aneuploidy comprising (a) selecting a chromosomal segment that hybridizes to a single locus comprising a segment of the chromosome comprising the aneuploidy to be detected; (b) selecting a chromosomal segment having at least 15% to 25% unique sequence such that at least 75% to 85% of the sequence within the chromosomal segment is repetitive, except for chromosomal segments from the X chromosome or Y chromosome, which can have up to 90% to 95% repetitive sequences; and (c) selecting a segment selected in both step (a) and step (b), thereby selecting a genomic nucleic acid segment for use as a hybridization target in a comparative genomic hybridization (CGH) reaction for the detection of a chromosomal aneuploidy. 52. The method of claim 51 comprising selecting a chromosomal segment having at least 15% unique sequence. 53. A compilation of nucleic acids for diagnosis of a genetic syndrome, the compilation comprising a plurality of nucleic acid segments, wherein each nucleic acid segment comprises a segment of genomic nucleic acid selected to detect a genetic syndrome, wherein the nucleic acid segments further comprise a compound having the general formula: R1--X--R2, wherein R1 is a cyclic ether, an aldehyde, or a chloromethylphenyl moiety; X is a moiety chemically suitable for linking the R1 moiety to the R2 moiety, and the R2 moiety has the general formula wherein R3, R4 and R5 comprise identical or different alkoxy groups or chloro groups. 54. The compilation of nucleic acids of claim 53, wherein the nucleic acid segments further comprise a cloning vehicle. 55. The compilation of nucleic acids of claim 53, wherein the nucleic acid segments are immobilized onto a surface. 56. The compilation of nucleic acids of claim 55, wherein the nucleic acid segments are immobilized on a surface as an array. 57. The compilation of nucleic acids of claim 53, wherein about 95% of the nucleic acid segments comprise a label. 58. The compilation of nucleic acids of claim 53, wherein about 98% of the nucleic acid segments comprise a label. 59. The compilation of nucleic acids of claim 53, wherein 100% of the nucleic acid segments comprise a label. 60. The compilation of nucleic acids of claim 53, wherein at least one nucleic acid segment is cloned in a construct comprising an artificial chromosome. 61. The compilation of nucleic acids of claim 60, wherein the artificial chromosome comprises a bacterial artificial chromosome (BAC). 62. The compilation of nucleic acids of claim 60, wherein the artificial chromosome is selected from the group consisting of a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), a transformation-competent artificial chromosome (TAC) and a bacteriophage P1-derived artificial chromosome (PAC). 63. The compilation of nucleic acids of claim 53, wherein at least one nucleic acid segment is cloned in a construct comprising a vector selected from the group consisting of a cosmid vector, a plasmid vector and a viral vector. 64. The compilation of nucleic acids of claim 53, wherein the nucleic acid segments are between about 50 kilobases to about 500 kilobases in length. 65. The compilation of nucleic acids of claim 64, wherein the nucleic acid segments are between about 100 kilobases to about 400 kilobases in length. 66. The compilation of nucleic acids of claim 65, wherein the cloned nucleic acid segments are between about 150 kilobases and about 300 kilobases in length. 67. A compilation of nucleic acids for diagnosis of a genetic syndrome, the compilation comprising a plurality of nucleic acid segments, wherein each nucleic acid segment comprises a segment of genomic nucleic acid selected to detect a genetic syndrome, wherein the nucleic acid segments further comprise a compound having the general formula: R1--X--R2, wherein R1 is an amino group, R2 is an alkoxysilane group or a chlorohalide group; and X is a moiety chemically suitable for linking the R1 group and the R2 group. 68. The compilation of nucleic acids of claim 67, wherein the nucleic acid segments further comprise a cloning vehicle. 69. The compilation of nucleic acids of claim 67, wherein the nucleic acid segments are immobilized onto a surface. 70. The compilation of nucleic acids of claim 69, wherein the nucleic acid segments are immobilized on a surface as an array. 71. The compilation of nucleic acids of claim 67, wherein about 95% of the nucleic acid segments comprise a label. 72. The compilation of nucleic acids of claim 67, wherein about 98% of the nucleic acid segments comprise a label. 73. The compilation of nucleic acids of claim 67, wherein 100% of the nucleic acid segments comprise a label. 74. The compilation of nucleic acids of claim 67, wherein at least one nucleic acid segment is cloned in a construct comprising an artificial chromosome. 75. The compilation of nucleic acids of claim 74, wherein the artificial chromosome comprises a bacterial artificial chromosome (BAC). 76. The compilation of nucleic acids of claim 74, wherein the artificial chromosome is selected from the group consisting of a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), a transformation-competent artificial chromosome (TAC) and a bacteriophage P1-derived artificial chromosome (PAC). 77. The compilation of nucleic acids of claim 67, wherein at least one nucleic acid segment is cloned in a construct comprising a vector selected from the group consisting of a cosmid vector, a plasmid vector and a viral vector. 78. The compilation of nucleic acids of claim 67, wherein the nucleic acid segments are between about 50 kilobases to about 500 kilobases in length. 79. The compilation of nucleic acids of claim 78, wherein the nucleic acid segments are between about 100 kilobases to about 400 kilobases in length. 80. The compilation of nucleic acids of claim 79, wherein the cloned nucleic acid segments are between about 150 kilobases and about 300 kilobases in length. 81. An array comprising: a plurality of nucleic acid segments, wherein each nucleic acid segment is immobilized to a discrete and known spot on a substrate surface to form an array of nucleic acids, and each spot comprises a segment of genomic nucleic acid selected to detect a genetic syndrome, wherein the array-immobilized genomic nucleic acid segments are covalently bound to the substrate surface through a compound having the general formula description="In-line Formulae" end="lead"R1--X--Si(OR2)m(Cl)n(R) k,description="In-line Formulae" end="tail" wherein m+k is the integer 3, and n can be 0 if m is greater than 0, or n+k is the integer 3 and m can be 0 if n is greater than 0; X is an inert linker; R1 comprises a group reactive toward a biological molecule; R is an alkyl group; and, R2 is an alkyl group. 82. The array of claim 81, further comprising at least one spot comprising a nucleic acid segment acting as a positive control. 83. The array of claim 81, further comprising at least one spot comprising a nucleic acid segment acting as a negative control. 84. The array of claim 81, wherein the array-immobilized genomic nucleic acid segments in a first spot are non-overlapping in sequence compared to the array-immobilized genomic nucleic acid segments in a second spot. 85. The array of claim 84, wherein the array-immobilized genomic nucleic acid segments in the first spot are non-overlapping in sequence compared to the array-immobilized genomic nucleic acid segments in all other genomic nucleic acid-comprising spots on the array. 86. The array of claim 81, wherein at least one genomic nucleic acid segment is spotted in duplicate or triplicate on the array. 87. The array of claim 86, wherein the duplicate spot or triplicate spot has a different amount of nucleic acid segments immobilized. 88. The array of claim 86, wherein all the genomic nucleic acid segments are spotted in duplicate or triplicate on the array. 89. The array of claim 81, wherein about 95% of the array-immobilized genomic nucleic acid segments comprise a label. 90. The array of claim 81, wherein about 98% of the array-immobilized genomic nucleic acid segments comprise a label. 91. The array of claim 81, wherein 100% of the array-immobilized genomic nucleic acid segments comprise a label. 92. The array of claim 81, wherein at least one nucleic acid segment is cloned in a construct comprising an artificial chromosome. 93. The array of claim 92, wherein the artificial chromosome comprises a bacterial artificial chromosome (BAC). 94. The array of claim 92, wherein the artificial chromosome is selected from the group consisting of a human artificial chromosome (HAC) a yeast artificial chromosome (YAC), a transformation-competent artificial chromosome (TAC) and a bacteriophage P1-derived artificial chromosome (PAC). 95. The array of claim 81, wherein at least one nucleic acid segment is cloned in a construct comprising a vector selected from the group consisting of a cosmid vector, a plasmid vector and a viral vector. 96. The array of claim 81, wherein at least one of the nucleic acid segments is between about 50 kilobases to about 500 kilobases in length. 97. The array of claim 96, wherein the at least one nucleic acid segment is between about 100 kilobases to about 400 kilobases in length. 98. The array of claim 97, wherein the at least one nucleic acid segment is about 300 kilobases in length.